These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22156765)

  • 41. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
    Baur M; Schernhammer E; Gneist M; Sevelda P; Speiser P; Hudec M; Dittrich Ch
    Br J Cancer; 2005 Mar; 92(6):1019-25. PubMed ID: 15756278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
    Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
    Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
    Shoji T; Takatori E; Omi H; Kumagai S; Yoshizaki A; Yokoyama Y; Mizunuma H; Fujimoto T; Takano T; Yaegashi N; Tase T; Nakahara K; Kurachi H; Nishiyama H; Sugiyama T
    Int J Gynecol Cancer; 2011 Jan; 21(1):44-50. PubMed ID: 21330830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Mayer AR; Homesley HD
    J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
    Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
    Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
    Pecorelli S; Ray-Coquard I; Tredan O; Colombo N; Parma G; Tisi G; Katsaròs D; Lhommé C; Lissoni AA; Vermorken JB; du Bois A; Poveda A; Frigerio L; Barbieri P; Carminati P; Brienza S; Guastalla JP
    Ann Oncol; 2010 Apr; 21(4):759-765. PubMed ID: 19906760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
    Verschraegen CF; Gupta E; Loyer E; Kavanagh JJ; Kudelka AP; Freedman RS; Edwards CL; Harris N; Steger M; Steltz V; Giovanella BC; Stehlin JS
    Anticancer Drugs; 1999 Apr; 10(4):375-83. PubMed ID: 10378672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study.
    Terauchi F; Hirano T; Taoka H; Masaki K; Yamamoto Y; Ogura H; Kubo H
    Int J Clin Oncol; 2003 Dec; 8(6):348-51. PubMed ID: 14663635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
    de Wit R; van der Burg ME; van den Gaast A; Logmans A; Stoter G; Verweij J
    Ann Oncol; 1994 Sep; 5(7):656-7. PubMed ID: 7993845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.
    Molina JR; Reid JM; Erlichman C; Sloan JA; Furth A; Safgren SL; Lathia CD; Alberts SR
    Anticancer Drugs; 2005 Oct; 16(9):997-1002. PubMed ID: 16162976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.
    Comander AH; Cannistra SA
    Int J Gynecol Cancer; 2008; 18(1):51-8. PubMed ID: 17506844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
    Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
    J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
    Morgan RD; Clamp AR; Hasan J; Mitchell C; Saunders G; Mescallado N; Welch R; Jayson GC
    Int J Gynecol Cancer; 2018 Mar; 28(3):448-452. PubMed ID: 29466253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.
    Lee GJ; Min JW; Seo MW; Lee MY; Jin JY
    J Obstet Gynaecol Res; 2014 Jan; 40(1):297-300. PubMed ID: 24102892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
    Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Mastrangelo S; Maurizi P; Migliorati R; Bertolini P; Pastore M; Colosimo C; Riccardi R
    Eur J Cancer; 2010 Nov; 46(16):2943-9. PubMed ID: 20538454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.
    Pein F; Pinkerton R; Berthaud P; Pritchard-Jones K; Dick G; Vassal G
    Eur J Cancer; 2007 Sep; 43(14):2074-81. PubMed ID: 17716890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
    McGregor LM; Spunt SL; Santana VM; Stewart CF; Ward DA; Watkins A; Laningham FH; Ivy P; Furman WL; Fouladi M
    Cancer; 2009 Feb; 115(3):655-64. PubMed ID: 19117350
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
    Clamp A; Adams M; Atkinson R; Boven E; Calvert AH; Cervantes A; Ganesan T; Lotz J; Vasey P; Cheverton P; Jayson GC
    Gynecol Oncol; 2004 Oct; 95(1):114-9. PubMed ID: 15385119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    Park SJ; Chang SJ; Suh DH; Kong TW; Song H; Kim TH; Kim JW; Kim HS; Lee SJ
    BMC Cancer; 2022 Jan; 22(1):28. PubMed ID: 34980026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
    Bruzzone M; Centurioni MG; Giglione P; Gualco M; Merlo DF; Miglietta L; Cosso M; Giannelli F; Cristoforoni P; Ferrarini M
    Oncology; 2011; 80(3-4):238-46. PubMed ID: 21734415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.